GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TScan Therapeutics Inc (NAS:TCRX) » Definitions » Degree of Operating Leverage

TCRX (TScan Therapeutics) Degree of Operating Leverage : -0.86 (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is TScan Therapeutics Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. TScan Therapeutics's Degree of Operating Leverage for the quarter that ended in Sep. 2024 was -0.86. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for TScan Therapeutics's Degree of Operating Leverage or its related term are showing as below:

TCRX's Degree of Operating Leverage is ranked better than
72.98% of 903 companies
in the Biotechnology industry
Industry Median: -0.01 vs TCRX: -0.86

TScan Therapeutics Degree of Operating Leverage Historical Data

The historical data trend for TScan Therapeutics's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TScan Therapeutics Degree of Operating Leverage Chart

TScan Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Degree of Operating Leverage
- - 0.10 1.01 1.18

TScan Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -329.91 1.18 3.48 -5.97 -0.86

Competitive Comparison of TScan Therapeutics's Degree of Operating Leverage

For the Biotechnology subindustry, TScan Therapeutics's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TScan Therapeutics's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TScan Therapeutics's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where TScan Therapeutics's Degree of Operating Leverage falls into.



TScan Therapeutics Degree of Operating Leverage Calculation

TScan Therapeutics's Degree of Operating Leverage for the quarter that ended in Sep. 2024 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -107.582 (Sep. 2024) / -85.915 (Sep. 2023) - 1 )/( 9.362 (Sep. 2024) / 13.278 (Sep. 2023) - 1 )
=0.2522/-0.2949
=-0.86***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


TScan Therapeutics  (NAS:TCRX) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


TScan Therapeutics Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of TScan Therapeutics's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


TScan Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
830 Winter Street, Waltham, MA, USA, 02451
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Executives
Lynx1 Capital Management Lp 10 percent owner 151 CALLE DE SAN FRANCISCO, SUITE 200 PMB 1237, SAN JUAN PR 00901-1607
Barbara Klencke director C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
Zoran Zdraveski officer: Chief Legal Officer C/O MAGENTA THERAPEUTICS, 50 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Timothy J Barberich director 40 ELM ST, CONCORD MA 01752
Leiden Dworak officer: Chief Accounting Officer C/O TSCAN THERAPEUTICS, INC., 880 WINTER STREET, WALTHAM MA 02451
Weston Nichols 10 percent owner C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Brian M. Silver officer: Chief Financial Officer C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Debora Barton officer: Chief Medical Officer C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
David P Southwell director, officer: Chief Executive Officer C/O INOTEK PHARMACEUTICALS CORPORATION, 91 HARTWELL AVENUE, LEXINGTON MA 02421
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Felix Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014